» Articles » PMID: 14985072

Troponin I Phosphorylation Plays an Important Role in the Relaxant Effect of Beta-adrenergic Stimulation in Mouse Hearts

Overview
Journal Cardiovasc Res
Date 2004 Feb 27
PMID 14985072
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The present study was designed to address the question of the contribution of cardiac troponin I (cTnI) phosphorylation to the enhanced rate of relaxation during beta-adrenergic stimulation in hearts in situ.

Methods: In situ hemodynamic measurements were performed in mouse hearts that (1) express normal level of phospholamban (PLB) and either express cTnI (PLB/cTnI) or the slow skeletal isoform of TnI (PLB/ssTnI) that cannot be phosphorylated by protein kinase A (PKA) or (2) do not express PLB and either express cTnI (PLBKO/cTnI) or ssTnI (PLBKO/ssTnI).

Results: In the basal state, there was no difference in heart rate (HR), developed pressure (DP), left ventricular end-diastolic pressure (LVEDP) or rate of contraction (+dP/dt) between PLB/cTnI and PLB/ssTnI groups. However, hearts expressing ssTnI (PLB/ssTnI) showed a significantly decreased rate of relaxation (-dP/dt) when compared with hearts expressing cTnI (PLB/cTnI). In response to beta-adrenergic agonist, isoproterenol (ISO), HR increased similarly in both groups. At the two highest doses of ISO, the rate of relaxation (-dP/dt) was significantly smaller in PLB/ssTnI than in PLB/cTnI hearts. In the basal state, there was no difference in HR, DP, LVEDP,+dP/dt and -dP/dt between PLBKO/cTnI and PLBKO/ssTnI hearts. In response to ISO, HR increased similarly in both groups and was only slightly smaller in PLBKO/ssTnI group at the lowest dose of ISO. However, during ISO perfusion, when cTnI was phosphorylated, the rate of relaxation was significantly slower in PLBKO/ssTnI compared to PLBKO/cTnI hearts.

Conclusion: Our data support the hypothesis that phosphorylation of cTnI significantly contributes to the enhanced rate of relaxation during beta-adrenergic stimulation.

Citing Articles

Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF.

Dominic K, Schmidt A, Granzier H, Campbell K, Stelzer J Front Physiol. 2024; 15:1512550.

PMID: 39726859 PMC: 11669688. DOI: 10.3389/fphys.2024.1512550.


Abnormal phosphorylation / dephosphorylation and Ca dysfunction in heart failure.

Liu Y, Wang Q, Song Y, Song X, Fan Y, Kong L Heart Fail Rev. 2024; 29(4):751-768.

PMID: 38498262 DOI: 10.1007/s10741-024-10395-w.


Tri-modal regulation of cardiac muscle relaxation; intracellular calcium decline, thin filament deactivation, and cross-bridge cycling kinetics.

Biesiadecki B, Davis J, Ziolo M, Janssen P Biophys Rev. 2017; 6(3-4):273-289.

PMID: 28510030 PMC: 4255972. DOI: 10.1007/s12551-014-0143-5.


CaMKII-dependent myofilament Ca2+ desensitization contributes to the frequency-dependent acceleration of relaxation.

Guilbert A, Lim H, Cheng J, Wang Y Cell Calcium. 2015; 58(5):489-99.

PMID: 26297240 PMC: 4662934. DOI: 10.1016/j.ceca.2015.08.001.


Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failure.

Wilson K, Guggilam A, West T, Zhang X, Trask A, Cismowski M Am J Physiol Heart Circ Physiol. 2014; 307(11):H1605-17.

PMID: 25260618 PMC: 4255015. DOI: 10.1152/ajpheart.00423.2014.